Tumor control and objective responses:: single-center experience with Ecteinascidin-743 (ET-743, Yondelis), an active compound for the treatment of patients with advanced soft tissue and bone sarcomas

被引：0
|
作者：
Huygh, G
Schöffski, P
Wildiers, H
Dumez, H
Van Oosterom, AT
Jimeno, JM
Selleslagh, J
Sciot, R
De Wever, I
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Pharmamar SA, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：311 / 312
页数：2
相关论文
共 14 条
  • [1] Tumor control and objective responses:: single-center experience with ecteinascidin-743 (ET-743), an active compound for the treatment of patients with advanced soft tissue and bone sarcomas.
    Schöffski, P
    Huygh, G
    Clement, P
    Jimeno, JM
    Wildiers, H
    Dumez, H
    Selleslach, J
    Sciot, R
    de Wever, I
    van Oosterom, AT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 822S - 822S
  • [2] Ecteinascidin-743 (ET-743): Early test or effective treatment in soft tissue sarcomas?
    Verweij, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5420 - 5423
  • [3] Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
    Garcia-Carbonero, R
    Supko, JG
    Maki, RG
    Manola, J
    Ryan, DP
    Harmon, D
    Puchalski, TA
    Goss, G
    Seiden, MV
    Waxman, A
    Quigley, MT
    Lopez, T
    Sancho, MA
    Limeno, J
    Guzman, C
    Demetri, GD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5484 - 5492
  • [4] Ecteinascidin-743 (ET-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: Results from phase II trials.
    Demetri, G
    Garcia-Carbonero, R
    Harmon, D
    Seiden, M
    Jimeno, J
    Merriam, P
    Waxman, A
    Supko, J
    Quigley, MT
    Ryan, D
    ANNALS OF ONCOLOGY, 2000, 11 : 126 - 126
  • [5] Experience of the use of trabectedin (ET-743, Yondelis™) in 21 patients with pre-treated advanced sarcoma from a single centre
    Roylance, R.
    Seddon, B.
    McTiernan, A.
    Sykes, K.
    Daniels, S.
    Whelan, J.
    CLINICAL ONCOLOGY, 2007, 19 (08) : 572 - 576
  • [6] Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
    Le Cesne, A
    Blay, JY
    Judson, I
    Van Oosterom, A
    Verweij, J
    Radford, J
    Lorigan, P
    Rodenhuis, S
    Ray-Coquard, I
    Bonvalot, S
    Collin, F
    Jimeno, J
    Di Paola, E
    Van Glabbeke, M
    Nielsen, OS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) : 576 - 584
  • [7] Experience of the use of trabectedin (ET-743) in patients with advanced soft tissue sarcoma failing doxorubicin and/or ifosfamide in Korea
    Kim, H.
    Ahn, J.
    Lee, H.
    Kim, T. M.
    Lee, J.
    Park, K.
    Sym, S.
    Choi, Y.
    Lee, K.
    Rha, S. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial (vol 23, pg 576, 2005)
    Le Cesne
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5276 - 5276
  • [9] Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute
    Mohan, V.
    Chawla, T.
    Alzwahereh, K.
    Jeong, W.
    Kita, K. Y.
    Chua, V. S.
    Kalra, A.
    Rana, G. S.
    Chawla, S. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] The Role of a Multidisciplinary Team in the Diagnosis and Treatment of Bone and Soft Tissue Sarcomas: A Single-Center Experience
    Pang, Ke
    Guo, Xiaoning
    Liu, Tang
    Wang, Lu
    Chen, Ruiqi
    Zhang, Zhiming
    Li, Lan
    He, Yu
    Zhang, Haixia
    Fan, Songqing
    Tu, Chao
    Li, Zhihong
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (12):
12